MedTrace Logo

Transitioning From Cyclosporine to Alefacept in Psoriasis

NCT00143806 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2009-01-05

No results posted yet for this study

Summary

The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.

Conditions

Interventions

DRUG

Transitioning patients from cyclosporine to alefacept

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • University of Medicine and Dentistry of New Jersey

    lead OTHER

Principal Investigators

  • Alice Gottlieb, MD, PhD · Rutgers, The State University of New Jersey

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143806 on ClinicalTrials.gov